S. Murray Sherman to Carcinoma, Neuroendocrine
This is a "connection" page, showing publications S. Murray Sherman has written about Carcinoma, Neuroendocrine.
Connection Strength
0.465
-
A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer. Clin Cancer Res. 2016 Jan 01; 22(1):44-53.
Score: 0.439
-
Thyroid carcinoma, version 2.2014. J Natl Compr Canc Netw. 2014 Dec; 12(12):1671-80; quiz 1680.
Score: 0.026